Table 1.
Participant characteristics at enrollment.
| Age (years) | 44 ± 4.0 |
| Gender (n) | |
| Women | 12 |
| Men | 0 |
| Height (cm) | 160 ± 1.0 |
| Weight (kg) | 79 ± 6.8 |
| BMI | 30 ± 2.8 |
| 6MWD (m) | 482 ± 17 |
| PAH etiology (n) | |
| Idiopathic | 8 |
| Connective tissue disease | 1 |
| Congenital heart disease | 3 |
| NYHA class (n) | |
| II | 6 |
| III | 6 |
| Co-morbidities (n) | |
| Hypertension | 3 |
| Diabetes mellitus | 1 |
| Hyperlipidemia | 3 |
| Obstructive sleep apnea | 3 |
| Oxygen use (n) | 2 |
| PAH therapy (n) | |
| Prostacyclin | 4 |
| Ca + channel blocker | 2 |
| ERA | 2 |
| PDE5 inhibitor | 9 |
| Hemodynamics | |
| mPAP (mmHg) | 44 ± 5 |
| PAWP (mmHg) | 12 ± 2 |
| PVR (WU) | 6.6 ± 1.5 |
| Cardiac index (mL/min/m2) | 3.1 ± 0.3 |
Chart values obtained at time of enrollment for the 12 enrolled patients are presented as n, or as means ± SEM where indicated.
BMI, body mass index; 6MWD, 6-min walk distance; PAH, pulmonary arterial hypertension; NYHA, New York Heart Association; ERA, endothelin receptor antagonist; PDE, phosphodiesterase; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance.